Charles River Laboratories Intl. Inc vs Dell Technologies Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Dell Technologies Inc trades at $586.28 (market cap $365.31B). The key difference: Dell Technologies Inc is far larger — about 25.7× Charles River Laboratories Intl. Inc's market cap, and Dell Technologies Inc pays a 0.44% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Dell Technologies Inc for 57 Days on average.
| CRL | DELL | |
|---|---|---|
Market Cap | $14.23B | $365.31B |
Volume | 1,176,885 | 5,121,365 |
Sector | Health | Technology |
52-Week High | $310.77 | $588.67 |
52-Week Low | $149.93 | $111.10 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $17.06B | $388.20B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Dell Technologies trades at $574.74, down 0.73% on the day, with strong bullish momentum driven by AI server demand. The stock shows robust earnings performance with three consecutive quarterly beats and raised 2027 AI revenue guidance to $74 billion. Technical indicators signal bullish momentum while fundamentals reveal strong revenue growth and improving profit margins, though valuation multiples appear elevated.
Outlook remains positive with AI server backlog reaching $95 billion and institutional support, though risks include execution challenges and competitive pressures in the rapidly evolving AI infrastructure market. The stock trades near analyst consensus target of $566.35 with upside potential to $735 based on AI-driven growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →